Fig. 1
From: KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
Treatment response to KRAS-G12C inhibitor therapy. A Objective response rates (ORR) of KRAS-G12C inhibitor monotherapy; B ORR of KRAS-G12C inhibitor combined with Cetuximab; C disease control rates (DCR) of KRAS-G12C inhibitor monotherapy. PP: pooled proportion; CI: confidence interval